Cytomab Rituximab 500 mg

Cytomab is a prescription drug used to treat blood cancer (Chronic lymphocytic leukemia),non-Hodgkin lymphoma (NHL) and rheumatoid arthritis . To buy Cytomab or to know its price contact 3S Corporation.

Manufacturer : Alkem Laboratories Ltd

Strengths available :  500 mg

Form :Injection

Dosage : Low-Grade or Follicular Non-Hodgkin’s Lymphoma: Initial Treatment: The recommended dosage of Cytomab used as monotherapy for adult patients is 375 mg/m2 body surface area, administered as an IV infusion once weekly for 4 weeks. The recommended dosage of Cytomab in combination with any chemotherapy is 375 mg/m2 body surface area per cycle, for a total of 8 cycles with R-CVP (21 days/cycle)/8 cycles with R-MCP (28 days/cycle)/8 cycles with R-CHOP (21 days/cycle); 6 cycles if a complete remission is achieved after 4 cycles/6 cycles with R-CHVP-Interferon (21 days/cycle). Cytomab/Cytomab should be administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of the chemotherapy, if applicable.Retreatment Following Relapse: Patients who have responded to Cytomab initially have been treated again with Cytomab at a dose of 375 mg/m2 body surface area, administered as an IV infusion once weekly for 4 weeks.Maintenance Treatment: Previously untreated follicular lymphoma patients after response to induction treatment may receive maintenance therapy with Cytomab given at 375 mg/m2 body surface area once every 2 months until disease progression or for a maximum period of 2 years.Relapsed/refractory patients after response to induction treatment may receive maintenance therapy with Cytomab given at 375 mg/m2 body surface area once every 3 months until disease progression or for a maximum period of 2 years.

Diffuse Large B-Cell Non-Hodgkin’s Lymphoma: Cytomab should be used in combination with CHOP chemotherapy. The recommended dosage of Cytomab is 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles after IV administration of the corticosteroid component of CHOP. The other components of CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine) should be given after the administration of Cytomab.

First Infusion: The recommended initial infusion rate is 50 mg/hr; subsequently, the rate can be escalated in 50-mg/hr increments every 30 min to a maximum of 400 mg/hr.

Subsequent Infusions: Subsequent infusions of Cytomab can be started at a rate of 100 mg/hr and increased by 100-mg/hr increments every 30 min to a maximum of 400 mg/hr.

Dosage Adjustments During Treatment: No dose reductions of Cytomab are recommended. When Cytomab is given in combination with CHOP chemotherapy, standard dose reductions for the chemotherapeutic drugs should be applied.

Maintenance Treatment: Patients who have responded to induction treatment may receive maintenance therapy with Cytomab given at 375 mg/m2 body surface area once every 3 months until disease progression or for a maximum period of 2 years.

Chronic Lymphocytic Leukemia: Prophylaxis with adequate hydration and administration of uricostatics starting 48 hrs prior to start of therapy is recommended for CLL patients to reduce the risk of tumourlysis syndrome. For CLL patients whose lymphocyte counts are >25 x 109/L, it is recommended to administer prednisone/prednisolone 100-mg IV shortly before infusion with Cytomab/Cytomab to decrease the rate and severity of acute infusion reactions and/or cytokine-release syndrome. The recommended dosage of Cytomab/Cytomab in combination with chemotherapy is 375 mg/m2 BSA administered on day 1 of the 1st treatment cycle followed by 500 mg/m2 BSA administered on day 1 of each subsequent cycle for 6 cycles in total. The chemotherapy should be given after Cytomab/Cytomab infusion.

Rheumatoid Arthritis: A course of Cytomab/Cytomab consists of two 1000 mg IV infusions. The recommended dosage of Cytomab/Cytomab is 1000 mg by IV infusion followed 2 weeks later by the 2nd 1000 mg IV infusion. The need for further courses should be evaluated 24 weeks following the previous course with re-treatment given based on residual or disease activity returning to a level above a DAS28-ESR of 2.6 (treatment to remission). Patients may receive further courses no sooner than 16 weeks following the previous course. Rheumatoid arthritis patients should receive treatment with methylprednisolone 100 mg IV 30 min prior to Cytomab/Cytomab to decrease the rate and severity of acute infusion reactions.

First Infusion of Each Course: Recommended initial rate for infusion is 50 mg/hr; after the first 30 min, it can be escalated in 50 mg/hr increments every 30 min, to a maximum of 400 mg/hr.

Second Infusion of Each Course: Subsequent doses of Cytomab can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 min intervals to a maximum of 400 mg/hr.

Storage :Store at 2 °C to 8 °C

Common side effects are edema, headache, weakness, itching, infection, hair loss, infusion reaction, decreased neutrophils, febrile neutropenia.

Pack of 1 vial